Clinical Trial Update: An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 [Phase 2]

View source ↗

Summary

Phase 2 extension study results for Lumasiran (ALN-GO1) in participants with Primary Hyperoxaluria Type 1 have been reported. The trial is completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria Type

Drugs mentioned

• Lumasiran (lumasiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: PH1, Primary Hyperoxaluria | Phase 2 | Status: COMPLETED | Results posted: 2024-04-25